Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota
Abstract Background Crohn's disease (CD) is a chronic non-specific inflammatory bowel disease. Current CD therapeutics cannot fundamentally change the natural course of CD. Therefore, it is of great significance to find new treatment strategies for CD. Preclinical and clinical studies have show...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-09-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13287-022-03118-1 |
| _version_ | 1798036382651777024 |
|---|---|
| author | Fan Yang Beibei Ni Qiuli Liu Fangping He Li Li Xuemei Zhong Xiaofan Zheng Jianxi Lu Xiaoyan Chen Huizhu Lin Ruixuan Xu Yizhan He Qi Zhang Xiaoguang Zou Wenjie Chen |
| author_facet | Fan Yang Beibei Ni Qiuli Liu Fangping He Li Li Xuemei Zhong Xiaofan Zheng Jianxi Lu Xiaoyan Chen Huizhu Lin Ruixuan Xu Yizhan He Qi Zhang Xiaoguang Zou Wenjie Chen |
| author_sort | Fan Yang |
| collection | DOAJ |
| description | Abstract Background Crohn's disease (CD) is a chronic non-specific inflammatory bowel disease. Current CD therapeutics cannot fundamentally change the natural course of CD. Therefore, it is of great significance to find new treatment strategies for CD. Preclinical and clinical studies have shown that mesenchymal stromal cells (MSCs) are a promising therapeutic approach. However, the mechanism by which MSCs alleviate CD and how MSCs affect gut microbes are still unclear and need further elucidation. Methods We used 2,4,6-trinitrobenzenesulfonic acid (TNBS) to induce experimental colitis in mice and analysed the microbiota in faecal samples from the control group, the TNBS group and the TNBS + MSC group with faecal 16S rDNA sequencing. Subsequent analyses of alpha and beta diversity were all performed based on the rarified data. PICRUStII analysis was performed on the 16S rRNA gene sequences to infer the gut microbiome functions. Results MSC Treatment improved TNBS-induced colitis by increasing survival rates and relieving symptoms. A distinct bacterial signature was found in the TNBS group that differed from the TNBS + MSC group and controls. MSCs prevented gut microbiota dysbiosis, including increasing α-diversity and the amount of Bacteroidetes Firmicutes and Tenericutes at the phylum level and decreasing the amount of Proteobacteria at the phylum level. MSCs alleviated the increased activities of sulphur and riboflavin metabolism. Meanwhile some metabolic pathways such as biosynthesis of amino acids lysine biosynthesis sphingolipid metabolism and secondary bile acid biosynthesis were decreased in the TNBS group compared with the control group and the TNBS + MSC group Conclusions Overall, our findings preliminarily confirmed that colitis in mice is closely related to microbial and metabolic dysbiosis. MSC treatment could modulate the dysregulated metabolism pathways in mice with colitis, restoring the abnormal microbiota function to that of the normal control group. This study provides insight into specific intestinal microbiota and metabolism pathways linked with MSC treatment, suggesting a new approach to the treatment of CD. |
| first_indexed | 2024-04-11T21:12:06Z |
| format | Article |
| id | doaj.art-9a8ad80e7a314a54ab13d64285639053 |
| institution | Directory Open Access Journal |
| issn | 1757-6512 |
| language | English |
| last_indexed | 2024-04-11T21:12:06Z |
| publishDate | 2022-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj.art-9a8ad80e7a314a54ab13d642856390532022-12-22T04:03:00ZengBMCStem Cell Research & Therapy1757-65122022-09-0113111410.1186/s13287-022-03118-1Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiotaFan Yang0Beibei Ni1Qiuli Liu2Fangping He3Li Li4Xuemei Zhong5Xiaofan Zheng6Jianxi Lu7Xiaoyan Chen8Huizhu Lin9Ruixuan Xu10Yizhan He11Qi Zhang12Xiaoguang Zou13Wenjie Chen14Postdoctoral Research Station, Xinjiang Medical UniversityCell-Gene Therapy Translational Medicine Research Centre, The Third Affiliated Hospital, Sun Yat-Sen UniversityBiotherapy Centre, The Third Affiliated Hospital, Sun Yat-Sen UniversityDepartment of Hepatobiliary and Pancreatic Surgery, The Eighth Affiliated Hospital, Sun Yat-Sen UniversityDepartment of Respiratory and Critical Care Medicine, The First People’s Hospital of Kashi, The Affiliated Kashi Hospital of Sun Yat-Sen UniversityDepartment of Respiratory and Critical Care Medicine, The First People’s Hospital of Kashi, The Affiliated Kashi Hospital of Sun Yat-Sen UniversityBiotherapy Centre, The Third Affiliated Hospital, Sun Yat-Sen UniversityBiotherapy Centre, The Third Affiliated Hospital, Sun Yat-Sen UniversityBiotherapy Centre, The Third Affiliated Hospital, Sun Yat-Sen UniversityBiotherapy Centre, The Third Affiliated Hospital, Sun Yat-Sen UniversityBiotherapy Centre, The Third Affiliated Hospital, Sun Yat-Sen UniversityBiotherapy Centre, The Third Affiliated Hospital, Sun Yat-Sen UniversityBiotherapy Centre, The Third Affiliated Hospital, Sun Yat-Sen UniversityDepartment of Respiratory and Critical Care Medicine, The First People’s Hospital of Kashi, The Affiliated Kashi Hospital of Sun Yat-Sen UniversityBiotherapy Centre, The Third Affiliated Hospital, Sun Yat-Sen UniversityAbstract Background Crohn's disease (CD) is a chronic non-specific inflammatory bowel disease. Current CD therapeutics cannot fundamentally change the natural course of CD. Therefore, it is of great significance to find new treatment strategies for CD. Preclinical and clinical studies have shown that mesenchymal stromal cells (MSCs) are a promising therapeutic approach. However, the mechanism by which MSCs alleviate CD and how MSCs affect gut microbes are still unclear and need further elucidation. Methods We used 2,4,6-trinitrobenzenesulfonic acid (TNBS) to induce experimental colitis in mice and analysed the microbiota in faecal samples from the control group, the TNBS group and the TNBS + MSC group with faecal 16S rDNA sequencing. Subsequent analyses of alpha and beta diversity were all performed based on the rarified data. PICRUStII analysis was performed on the 16S rRNA gene sequences to infer the gut microbiome functions. Results MSC Treatment improved TNBS-induced colitis by increasing survival rates and relieving symptoms. A distinct bacterial signature was found in the TNBS group that differed from the TNBS + MSC group and controls. MSCs prevented gut microbiota dysbiosis, including increasing α-diversity and the amount of Bacteroidetes Firmicutes and Tenericutes at the phylum level and decreasing the amount of Proteobacteria at the phylum level. MSCs alleviated the increased activities of sulphur and riboflavin metabolism. Meanwhile some metabolic pathways such as biosynthesis of amino acids lysine biosynthesis sphingolipid metabolism and secondary bile acid biosynthesis were decreased in the TNBS group compared with the control group and the TNBS + MSC group Conclusions Overall, our findings preliminarily confirmed that colitis in mice is closely related to microbial and metabolic dysbiosis. MSC treatment could modulate the dysregulated metabolism pathways in mice with colitis, restoring the abnormal microbiota function to that of the normal control group. This study provides insight into specific intestinal microbiota and metabolism pathways linked with MSC treatment, suggesting a new approach to the treatment of CD.https://doi.org/10.1186/s13287-022-03118-1Mesenchymal stem cellsCrohn's diseaseTNBS16S rRNA gene sequencesGut microbiotaMetabolism |
| spellingShingle | Fan Yang Beibei Ni Qiuli Liu Fangping He Li Li Xuemei Zhong Xiaofan Zheng Jianxi Lu Xiaoyan Chen Huizhu Lin Ruixuan Xu Yizhan He Qi Zhang Xiaoguang Zou Wenjie Chen Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota Stem Cell Research & Therapy Mesenchymal stem cells Crohn's disease TNBS 16S rRNA gene sequences Gut microbiota Metabolism |
| title | Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota |
| title_full | Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota |
| title_fullStr | Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota |
| title_full_unstemmed | Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota |
| title_short | Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota |
| title_sort | human umbilical cord derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota |
| topic | Mesenchymal stem cells Crohn's disease TNBS 16S rRNA gene sequences Gut microbiota Metabolism |
| url | https://doi.org/10.1186/s13287-022-03118-1 |
| work_keys_str_mv | AT fanyang humanumbilicalcordderivedmesenchymalstemcellsameliorateexperimentalcolitisbynormalizingthegutmicrobiota AT beibeini humanumbilicalcordderivedmesenchymalstemcellsameliorateexperimentalcolitisbynormalizingthegutmicrobiota AT qiuliliu humanumbilicalcordderivedmesenchymalstemcellsameliorateexperimentalcolitisbynormalizingthegutmicrobiota AT fangpinghe humanumbilicalcordderivedmesenchymalstemcellsameliorateexperimentalcolitisbynormalizingthegutmicrobiota AT lili humanumbilicalcordderivedmesenchymalstemcellsameliorateexperimentalcolitisbynormalizingthegutmicrobiota AT xuemeizhong humanumbilicalcordderivedmesenchymalstemcellsameliorateexperimentalcolitisbynormalizingthegutmicrobiota AT xiaofanzheng humanumbilicalcordderivedmesenchymalstemcellsameliorateexperimentalcolitisbynormalizingthegutmicrobiota AT jianxilu humanumbilicalcordderivedmesenchymalstemcellsameliorateexperimentalcolitisbynormalizingthegutmicrobiota AT xiaoyanchen humanumbilicalcordderivedmesenchymalstemcellsameliorateexperimentalcolitisbynormalizingthegutmicrobiota AT huizhulin humanumbilicalcordderivedmesenchymalstemcellsameliorateexperimentalcolitisbynormalizingthegutmicrobiota AT ruixuanxu humanumbilicalcordderivedmesenchymalstemcellsameliorateexperimentalcolitisbynormalizingthegutmicrobiota AT yizhanhe humanumbilicalcordderivedmesenchymalstemcellsameliorateexperimentalcolitisbynormalizingthegutmicrobiota AT qizhang humanumbilicalcordderivedmesenchymalstemcellsameliorateexperimentalcolitisbynormalizingthegutmicrobiota AT xiaoguangzou humanumbilicalcordderivedmesenchymalstemcellsameliorateexperimentalcolitisbynormalizingthegutmicrobiota AT wenjiechen humanumbilicalcordderivedmesenchymalstemcellsameliorateexperimentalcolitisbynormalizingthegutmicrobiota |